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Abstract
Introduction: Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been
demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid
aggregation. It reduces pathology in transgenic models of Alzheimer’s disease (AD) and is a promising candidate
for treating human AD. The purpose of the current study is to generate tolerability and preliminary clinical and
biomarker efficacy data on curcumin in persons with AD.
Methods: We performed a 24-week randomized, double blind, placebo-controlled study of Curcumin C3 Complex
®
with an open-label extension to 48 weeks. Thirty-six persons with mild-to-moderate AD were randomized to receive
placebo, 2 grams/day, or 4 grams/day of oral curcumin for 24 weeks. For weeks 24 through 48, subjects that were
receiving curcumin continued with the same dose, while subjects previously receiving placebo were randomized in a
1:1 ratio to 2 grams/day or 4 grams/day. The primary outcome measures were incidence of adverse events, changes
in clinical laboratory tests and the Alzheimer’s Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at
24 weeks in those completing the study. Secondary outcome measures included the Neuropsychiatric Inventory
(NPI), the Alzheimer’s Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale, levels of Ab1-40 and Ab1-
42 in plasma and levels of Ab1-42, t-tau, p-tau181 and F2-isoprostanes in cerebrospinal fluid. Plasma levels of curcumin
and its metabolites up to four hours after drug administration were also measured.
Results: Mean age of completers (n = 30) was 73.5 years and mean Mini-Mental Status Examination (MMSE) score
was 22.5. One subject withdrew in the placebo (8%, worsened memory) and 5/24 subjects withdrew in the
curcumin group (21%, 3 due to gastrointestinal symptoms). Curcumin C3 Complex
® was associated with lowered
hematocrit and increased glucose levels that were clinically insignificant. There were no differences between
treatment groups in clinical or biomarker efficacy measures. The levels of native curcumin measured in plasma
were low (7.32 ng/mL).
Conclusions: Curcumin was generally well-tolerated although three subjects on curcumin withdrew due to
gastrointestinal symptoms. We were unable to demonstrate clinical or biochemical evidence of efficacy of
Curcumin C3 Complex
® in AD in this 24-week placebo-controlled trial although preliminary data suggest limited
bioavailability of this compound.
Trial registration: ClinicalTrials.gov Identifier: NCT00099710.
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More than five million Americans currently have Alzhei-
mer’s disease (AD) [1] and available treatments have
only modest symptomatic benefits. We are in desperate
need of readily available, safe interventions that modify
disease course. Curcumin is a polyphenolic compound
derived from the plant Curcuma Long Lin that has been
used as a food preservative and to treat various ailments
in Ayurvedic medicine. In vitro and in vivo animal stu-
dies have demonstrated that curcumin has potentially
important biological effects including anti-oxidant and
anti-inflammatory properties [2]. As oxidative stress [3]
and inflammation [4] are potentially involved in propa-
gating AD pathology, the utility of curcumin in treating
and preventing AD is being pursued [5].
There is convergent evidence that overproduction,
aberrant aggregation, or decreased elimination of differ-
ent forms of amyloid beta protein (Ab) are critical
events in the pathogenesis of AD and, therefore, treat-
ment development has focused on these processes. Cur-
cumin has a biphenolic structure similar to Congo Red
and binds to amyloid plaques in vivo [6]. Curcumin pre-
vents Ab-induced toxicity in vitro in various prepara-
tions [7] and prevented the aggregation of Ab into
fibrils [8]. Transgenic mice harboring the amyloid pre-
cursor protein Swedish mutation (APPsw) fed curcumin
for six months had decreased levels of Ab and inflam-
matory cytokines in the brain [9]. The ability of curcu-
min to cross the blood-brain barrier, and bind to and
induce rapid dissolution of plaques was verified using
multi-photon microscopy in vivo in APPsw/PS1dE9
mice [10]. In further studies of curcumin and tetrahy-
drocurcumin in the Tg2576 APPsw mouse, curcumin
was found to reduce central nervous system levels of IL-
1b and isoprostanes (an index of oxidative stress) and to
reduce amyloid plaque burden [6].
Although there is extensive experience with human con-
sumption of turmeric oleoresin (85% curcumin) such that
it is classified as ‘Generally Recognized As Safe’ (GRAS) by
the US Food and Drug Administration, there is still much
to be determined about the tolerability and bioavailability
of moderate doses of curcumin when used chronically,
particularly in elderly individuals. Prior short-term human
studies suggest the potential for gastrointestinal side
effects including diarrhea [11] and toxicity studies in rats
indicate the possibility of hepatoxicity and thyroid follicu-
lar cell hyperplasia [12]. We, therefore, performed a 24-
week, randomized, double-blind, placebo-controlled study
of two doses of Curcumin C3 Complex
® in persons with
mild-to-moderate AD with an open-label extension to 48
weeks. The primary goals were to gather data on safety
and tolerability and preliminary data on efficacy with
regard to cognition. Secondary goals were to obtain preli-
minary efficacy data on behavior and activities of daily
living and on plasma and cerebrospinal fluid (CSF) AD
biomarkers.
Materials and methods
Participants
Thirty-six subjects with mild-to-moderate probable AD
were enrolled at the Mary S. Easton Center for Alzhei-
mer’s Disease Research at UCLA. Inclusion criteria were
the presence of dementia according to the Diagnostic
and Statistical Manual of Mental Disorders, fourth edi-
tion (DSM-IV) [13], a diagnosis of probable AD by the
National Institute of Neurological and Communicative
Disorders and Stroke - Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria [14],
age greater than 49 years, Mini-Mental Status Examina-
tion (MMSE) scores between 17 and 29, English profi-
ciency, and the availability of a study partner to monitor
medication administration and adverse effects. Dosage
of acetylcholinesterase inhibitors (AchE-I) and meman-
tine had to be stable for one month prior to enrollment.
Exclusion criteria included significant systemic illness or
recent history of gastrointestinal bleeding. Exclusionary
medications included aspirin at doses greater than 325
mg/day, use of non-steroidal anti-inflammatory drugs
more than three times a week, coumadin, heparin,
gingko biloba, and antioxidant supplements (for exam-
ple, coenzyme Q10 and alpha-lipoic acid). Concomitant
consumption of vitamin E at doses up to 2,000 i.u./day
and vitamin C up to 500 mg/day were allowed. To the
extent possible, doses of medications and supplements
were stable throughout the course of the trial.
A single block of 36 sequential assignments was ran-
domly created and the UCLA research pharmacy pack-
aged and distributed the investigational product
accordingly. All study personnel and subjects were
blinded to randomization sequence. An unblinded data
safety and monitoring board met by teleconference
before, and on three occasions during, the study. Subjects
or their legally authorized representatives provided writ-
ten informed consent prior to the initiation of any study
procedures. The protocol was approved by the UCLA
Institutional Review Board.
Intervention
Subjects were allocated to receive placebo, 2 gm, or 4 gm
of Curcumin C3 Complex
® per day in two divided doses
for 24 weeks in a 1:1:1 ratio. These doses were chosen
based on extrapolation from animal studies and allometric
scaling. Curcumin C3 Complex
® is an orange-yellow crys-
talline powder plant extract that was encapsulated and pro-
vided (as was the matching placebo) by Sabinsa
Corporation (Piscataway, NJ, USA). Curcumin C3 Com-
plex
® consists of 95% curcuminoids with 70% to 80%
comprised by curcumin, 15% to 25% demethoxycurcumin,
and 2.5% to 6.5% bisdemethoxycurcumin. This content
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Curcumin C3 Complex
® or placebo was administered
orally as four 500 mg capsules taken twice daily with a
fatty meal. At the 24-week visit, all subjects receiving pla-
cebo were randomized to one of the two doses of curcu-
min that was administered for another 24 weeks. Subjects
receiving 2 grams or 4 grams of curcumin in the first 24
weeks continued to 48 weeks on the same dose.
Outcome measures
Primary outcomes included tolerability and cognitive
measures. At baseline and each of the post-baseline vis-
its (weeks 4, 12, 24, 36, and 48) subjects and caregivers
were interviewed regarding adverse events using a
checklist. At screening and at each post-baseline visit,
vital signs were taken and laboratory value monitoring
performed including complete blood count, chemistry
panel, lipid profile, thyroid stimulating hormone and
thyroxine levels. Bleeding times before and after treat-
ment were also obtained on 24 subjects. The Alzhei-
mer’s Disease Assessment Scale, cognitive sub-portion
(ADAS-Cog) [15] was administered at baseline and at
the 24 and 48 week visits. The current paper describes
the results of efficacy outcome measures at 24 weeks
and tolerability measures out to 48 weeks.
Secondary clinical outcome measures included the
Neuropsychiatric Inventory (NPI) [16] and the Alzhei-
mer’s Disease Cooperative Study Activities of Daily
Living (ADCS-ADL) [17] instrument which were admi-
nistered to caregivers at baseline and at the 24 and 48
week visits. The MMSE was also administered at screen-
ing and at all post-baseline visits. Plasma and CSF were
collected at the baseline visit for biomarker measure-
ments; this was repeated at week 24. All samples were
centrifuged and frozen at -80°C. Commercially available
kits were used to measure plasma levels of Ab1-40 and
Ab1-42 (INNO-BIA Plasma Ab Forms; Innogenetics,
Ghent, Belgium) and CSF levels of Ab1-42, total tau (t-
tau), and tau phosphorylated at threonine 181 (p-tau181,
INNO-BIA AlzBio3; Innogenetics, Ghent, Belgium)
using the Luminex xMAP platform (Luminex, Austin
TX, USA). CSF isoprostanes (F2-IsoPs) were quantified
using a stable isotope dilution assay with gas chromato-
graphy/mass spectrometry and selective ion monitoring
as described previously [18]. All plasma and CSF assays
were done in a single batch at the end of the 24-week
study period.
Pharmacokinetic analysis
Pharmacokinetic analyses were performed in two differ-
ent manners in two different laboratories.
First, plasma levels of native curcumin at baseline and
at 0.5, 1, 2, 3, and 4 hours post-dose at the 24 week
visit were measured using HPLC as described previously
[19]. The coefficient of variation (CV) for a 20 ng/mL
sample was 4.95%. The lower limit of detection using
HPLC was 200 ng/mL.
Second, using liquid chromatography/tandem mass
spectrometry (LC/MS/MS) plasma (baseline levels and 3
hour post-dose at the 24 week visit) and CSF levels
(prior to the first dose and after the dose at the 24 week
visit) of native curcumin were measured. Curcumin was
extracted from plasma and CSF in 95% ethyl acetate/5%
methanol and analyzed by LC/MS/MS, using tetra-
methoxycurcumin as an internal standard as previously
described [6]. The LC/MS/MS system (Varian Interna-
tional, Lake Forest, CA, USA) consisted of the proStar
410 autosampler and pumps and a 310 mass spectro-
meter with ESI (-) which is able to optimize each ion
automatically. Dried plasma/CSF extract samples were
re-dissolved in acetonitrile:water (50/50, by volume) in
10 mM ammonium acetate, and an aliquot of the solu-
tion (typically 50 ul) was injected onto a reverse phase
HPLC column (Atlantis T3, 150 × 2.1 mm; Waters Cor-
poration, Milford, MA, USA). The m/z values of the
specific transitions were for curcumin, 367.0, 148.7,
172.4, 216.3, tetrahydrocurcumin, 372.0, 193.5, 236.0
and for tetramethoxycurcumin, 396.4, 149.5, 297.1,
337.6 (the internal standard). Instrument manufacturer-
supplied LC/MS/MS Varian software (Varian MS Work-
station, Version 6.9.1) was used to calculate each ion
according to its qualifier ion. The limit of detection for
curcumin and tetrahydrocurcumin in the plasma sample
was 1 and 3 ng/mL, respectively. To measure glucuro-
nides, 10 μL of 0.4 M PBS with 2% ascorbic acid and
0.1% ethylenediaminetetraacetic acid (EDTA) (pH 3.6)
were added to 0.5 ml plasma along with 30 μLo f0 . 1M
PBS (pH 6.8). Then, 500 Fishman units of b-glucuroni-
d a s e( S i g m a ,S tL o u i s ,M O ,U S A )w e r ea d d e dt ot h e
sample, which was incubated at 37°C for 45 minutes at
pH 5.0, followed by analysis of curcumin and tetrahy-
drocurcumin using LC/MS/MS.
Statistical analysis
The pre-specified data analysis plan for efficacy mea-
sures was repeated measures analyses of variance (ANO-
VAs) with drug dose as the independent variable and
cognitive, behavioral, and biomarker measures as the
dependent variables over time. Occurrence of adverse
events, changes in vital signs, and safety laboratory
results per subject according to the treatment they
r e c e i v e do v e rt h ec o u r s eo ft h es t u d yw e r ec o m p a r e d
between treatment groups by the general linear mixed
model.
Analyses of efficacy measures were performed on data
from completers due to lack of follow-up biomarker data
for subjects who discontinued. Analyses of safety and tol-
erability measures were performed on all available data
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no role in study design or outcome analysis.
Results
Eighty-four subjects were screened between August
2004 and January 2007 of whom 38 were randomized
(Figure 1). Two subjects never received study medica-
tion (one due to inability to swallow the capsules,
another due to intercurrent illness between randomiza-
tion and baseline visits) and their treatment allocations
were re-assigned. Thirty-six subjects therefore received
at least one dose of study medication (12 per group).
Among the 30 subjects who completed 24 weeks, base-
line gender (63% female), years of education (15.2
years), use of AchE-Is (93%) and memantine (77%),
average age (73.5 years), MMSE (22.5), total NPI (9.7),
ADAS-Cog (19.4), and ADCS-ADL (62.8) scores did not
differ among treatment groups (Table 1).
Between baseline and 24 weeks, six subjects withdrew.
One subject (8%) withdrew in the placebo group (wor-
sened memory) and 5/24 subjects (21%) in the curcumin
group withdrew due to adverse effects (P = 0.33). Among
the curcumin-treated subjects, three withdrew in the 2
gm/day curcumin group (two due to gastrointestinal side
effects of black stools and diarrhea, one due to subsequent
difficulty swallowing the pills), and two subjects withdrew
in the 4 gm/day curcumin group (one due to diarrhea and
one due to difficulty swallowing the pills). Of the 30 sub-
jects entering the open-label phase, two subjects originally
assigned to placebo dropped out before week 48, one due
to deterioration of AD symptoms and one due to weight
loss and a low hematocrit.
Overall, adverse events occurred in 91.7% of placebo-
treated subjects and 100% of curcumin treated subjects
(n.s.). Complaints attributable to the endocrine system
were less common in the 2 gm/day curcumin group,
occurring at 3% of visits, compared to the placebo group
(17%) and the 4 gm/day group (19%, P = 0.02). Patients
on placebo reported diarrhea on 4% of visits, patients on
2g m / d a yo fc u r c u m i na t6 %o fv i s i t sa n dp a t i e n t so n
4 gm/day on 8% of visits (P =0 . 6 3 ) .J o i n tp a i nw a s
reported at 15% of visits for persons on placebo, 9% of
visits for persons on 2 gm and 5% of persons on 4 gm of
curcumin (P = 0.19). When modeling the difference in
joint pain occurrence as a linear function of curcumin
dose, a 2.5% trend towards decrease in joint pain per
gram of curcumin was found (P = 0.07). There were no
serious adverse events in the course of this study.
Complete safety laboratory data at baseline and 24
weeks were available for 11 completers on placebo, 9 on
2 gm/day and 9 on 4 gm/day of curcumin. Controlling
for baseline values, subjects on curcumin had statisti-
cally lower hematocrit (placebo = 42.9%, standard error
of the mean (SEM) = 0.49, 2 gm = 41.8%, SEM = 0.55,
4 gm = 42.3%, SEM. = 0.54; P = 0.014) and higher glu-
cose levels (placebo = 85.9 mg/dL, SEM = 4.2, 2 gm =
91.6 mg/dL, SEM = 4.5; 4 gm = 90.5 mg/dL, SEM = 4.5,
P = 0.043) while being treated.
There were no differences between treatment groups in
change in ADAS-Cog, NPI, ADCS-ADL, or MMSE scores
using repeated measures ANOVA (Table 2). When the
2 gm/day and 4 gm/day curcumin groups were combined,
there was a trend for treated subjects to do worse
than placebo-treated subjects on the MMSE (P = 0.08).
2 Subjects Never Received Medication
1 - Unable to Swallow Pills
1 - Never Baselined due to Intercurrent Illness
1 subject withdrew:
Worsened memory
11 subjects completed week 24 visit
CSF available for 10
Placebo - 12 subjects
3 subjects withdrew:
2 due to GI side effects
1 due to difficulty swallowing pills
9 subjects completed week 24 visit
CSF available for 7
2 gm/day Curcumin - 12 subjects
2 subjects withdrew:
1 due to GI side effects
1 due to difficulty swallowing pills
10 subjects completed week 24 visit
CSF available for 8
4 gm/day Curcumin - 12 subjects
36 Subjects Baselined,
Received at least one dose of Medication
38 Subjects Randomized
84 Subjects Screened
Figure 1 Subject participation flow chart.
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ters in the placebo group, seven in the 2 gm/day group, and
for eight in the 4 gm/day group. There were no significant
effects of treatment group on change in plasma Ab1-40
and Ab1-42,C S FA b1-42,C S Ft a uo rp - t a uo rF 2-IsoPs
(Table 2).
Pharmacokinetic results
Using HPLC methods, levels of native curcumin were
undetectable in any sample at any time point post-dose
except for one sample four hours after a 4 gm dose (6 ng/
mL). Therefore, LC/MS/MS was used as a more sensitive
method to measure native curcumin and tetrahydrocurcu-
min and their glucuronidated metabolites. At the 24-week
visit the baseline mean plasma concentrations of native
curcumin and its free metabolite tetrahydrocurcumin were
2.67 ± 1.69 and 6.87 ± 4.91 ng/mL, respectively (< 10%
CV). Three hours after medication administration the
mean plasma concentrations of native curcumin and tetra-
hydrocurcumin were 7.76 ± 3.23 and 3.73 ± 2.0 ng/mL,
respectively. The levels of glucuronidated curcumin and
tetrahydrocurcumin were 96.05 ± 26 ng/mL and 298.2 ±
140.04 ng/mL. Plasma levels of curcumin were not detect-
able in placebo-treated subjects nor in persons prior
to treatment with curcumin. Levels of native curcumin
were undetectable in the CSF of placebo or curcumin-
treated subjects.
Discussion
In this 24-week double-blind placebo-controlled study
with a 24-week extension, we examined the tolerability
of 2 gm/day and 4 gm/day of Curcumin C3 Complex
®
in persons with mild-to-moderate AD. A total of 4/35
(11.4%) subjects dropped out of the study while on cur-
cumin, due to gastrointestinal side effects. Two subjects
had black stools consistent with melena but in no sub-
ject was there unequivocal evidence of gastrointestinal
hemorrhage or hemodynamic compromise. A subset of
subjects underwent bleeding time assessments and no
significant effect of curcumin was observed. The reason
for the observed increased plasma glucose levels in per-
sons treated with curcumin is unclear. These changes in
hematocrit and blood glucose were relatively minor and
values did not exceed the range of normal.
Following single doses of 2 gram and 4 gram doses of
Curcumin C3 Complex
°, we were unable to measure sig-
nificant plasma levels of native curcumin based on the
half maximal inhibitory concentration IC50’s identified in
Begum et al. [6]. Recent studies of curcumin suggest lim-
ited bioavailability [20], likely due to extensive metabo-
lism in the gastrointestinal tract. In animal models, the
diketone bridge of native curcumin was required for its
plaque-reducing effects, presumably due to its require-
ment for amyloid-binding [6]. As an equivocal ameliora-
tive peripheral effect on joint inflammation was
suggested by our findings, the current results do not
exclude a peripheral effect of glucuronidated curcumi-
noids, which were high, but as has been shown in mice
[21], not likely to penetrate the blood brain barrier. How-
ever, we did not observe an effect on F2-IsoP levels that
have been previously shown to be influenced by the
administration of curcumin in a rat model of Ab-induced
injury [22] and by antioxidants in humans [23]. Alterna-
tive formulations of curcumin that are better absorbed
are being studied [24] for their potential use in AD.
We were unable to demonstrate clinical or biochemical
evidence of efficacy against AD. Considering the small
sample size and short duration of this study, significant
impact on clinical indices was not expected. Additionally,
variability in the baseline disease severity may have masked
effects, particularly if the intervention was effective in a
subgroup (for example, persons with milder disease). How-
ever, there were non-significant trends for both MMSE
score and the ADAS-Cog score to worsen slightly in the
Table 1 Baseline characteristics of subjects who completed the 24-week, double blind, placebo controlled portion of
the study.
Placebo (n = 11) Curcumin 2 gm/day (n = 9) Curcumin 4 gm/day (n = 10)
Age in years 70.2 (12.4) 76.7 (5.6) 75.3 (6.9) P = 0.71
Gender, number of women (%) 6 (55%) 6 (67%) 7 (70%) P = 0.74
Years of education (S.D.) 14.3 (2.5) 16.7 (1.3) 15.0 (2.7) P = 0.08
Number on AchE-I’s (%) 11 (100%) 7 (78%) 10 (100%) P = 0.08
Number on memantine (%) 8 (73%) 7 (78%) 8 (80%) P = 0.92
MMSE (S.D., range) 23.2 (2.3, 20-27) 21.4 (3.2, 17-28) 22.8 (3.4, 18-27) P = 0.41
ADAS-Cog score (S.D.) 18.2 (4.9) 20.9 (7.4) 19.3 (3.4) P = 0.64
NPI total score (S.D.) 8.5 (12.4) 8.9 (9.6) 11.7 (16.9) P = 0.84
ADCS-ADL score (S.D.) 66.7 (3.6) (n = 10) 60.3 (10.9) 61.0 (8.4) P = 0.18
Note that ADCS-ADL score was not available on one subject in the placebo arm. AchE-I, acetylcholinesterase inhibitor; ADAS-Cog, Alzheimer’s Disease Assessment
Scale - Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study - Activities of Daily Living; MMSE, Mini-Mental State Examination; NPI,
Neuropsychiatric Inventory; S.D., standard deviation.
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Placebo (n = 11) 2 gm/day Curcumin (n = 9) 4 gm/day Curcumin (n = 10)
baseline week 24 change baseline week 24 change baseline week 24 change
MMSE 23.2 (2.3) 22.7 (2.3) -0.45 (2.6) 21.4 (3.2) 19.6 (3.9) - 1.89 (2.6) 22.8 (3.4) 19.9 (3.0) -2.90 (2.0) P = 0.08
ADAS-Cog 18.2 (4.9) 20.4 (7.1) 2.2 (5.0) 20.9 (7.4) 27.2 (11.7) 6.3 (8.1) 19.3 (3.4) 22.4 (4.4) 3.1 (3.4) P = 0.26
NPI total 8.5 (12.4) 10.3 (14.3) 1.8 (10.0) 8.9 (9.6) 11.0 (15.8) 2.1 (10.1) 11.7 (16.9) 6.9 (5.6) -4.8 (14.7) P = 0.35
ADCS-ADL 66.7 (3.6) 60.6 (9.5) -4.9 (7.6) 60.3 (10.9) 53.1 (15.4) -6.3 (6.8) 61.0 (8.4) 56.2 (9.4) -3.4 (6.5) P = 0.72
Plasma Ab42 (pg/mL) 28.7 (11.2) 31.4 (13.5) 2.7 (4.5) 25.3 (8.2) 25.3 (10.4) 0.0 (3.3) 29.6 (4.8) 30.5 (6.7) 0.9 (3.5) P = 0.98
Plasma Ab40 (pg/mL) 234.2 (60.3) 220.4 (74.9) -13.8 (64.9) 239.4 (41.8) 226.1 (27.3) -13.3 (39.6) 224.9 (38.5) 219.4 (57.6) -18.9 (58.1) P = 0.29
CSF Ab42 (pg/mL) 150.7 (26.2) 157.5 (32.0) 6.8 (19.8) 150.2 (35.0) 159.2 (30.8) 9.0 (17.0) 159.1 (27.2) 168.8 (30. 7) 9.7 (30.8) P = 0.96
CSF Total tau (pg/mL) 110.9 (75.9) 114.7 (82.9) 3.8 (27.9) 95.8 (31.5) 95.9 (23.2) 0.1 (14.5) 146.0 (78.0) 149.3 (81.1) 3.3 (38.3)) P = 0.97
CSF Phospho-tau (pg/mL) 48.6 (18.8) 51.3 (19.3) 2.7 (6.4) 49.8 (28.3) 55.6 (40.5) 5.8 (13.9) 61.0 (30.7) 65.8 (32.9) 4.8 (12.2) P = 0.83
CSF F2-IsoPs (ng/mL) 0.035 (0.005) 0.029 (0.009) -0.006 (0.008) 0.023 (0.005) 0.022 (0.005) -0.001 (0.005) 0.030 (0.008) 0.031 (0.013) 0.001 (0.009) P = 0.08
CSF analyses are for 10 subjects in the placebo group, seven in the 2 gm/day group, and eight in the 4 gm/day group. Two subjects in the 4 gm/day group were lacking valid plasma Ab40 levels and ADCS-ADL data
was missing on one subject in each group. Ab, amyloid beta; ADAS-Cog, Alzheimer’s Disease Assessment Scale - Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study - Activities of Daily Living; CSF,
cerebrospinal fluid; NPI, Neuropsychiatric Inventory; p-tau, phosphorylated tau.
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8curcumin-treated groups relative to placebo. Though the
small sample size and non-significance precludes definitive
conclusions from this observation, it is possible that cur-
cumin might exert a minor encephalopathic effect though
the mechanism of this would be unknown.
A prior six-month study of curcumin in 34 persons with
AD similarly failed to demonstrate an impact on clinical
measures [25]. This study similarly found high levels of
glucuronidated curcuminoids in plasma and a trend for
increased Ab40 with a 4 gram dose of curcumin was
noted, possibly reflecting mobilization of Ab40. However,
we did not observe such an effect in our study and no
effects on CSF AD biomarkers, including Ab42, were
found.
There have been relatively few clinical trials in which
comprehensive biomarker data have been collected at six-
month intervals. The data collected here show the baseline
and 24-week variation in plasma Ab, CSF Ab42, CSF t-tau
and p-tau181 and CSF isoprostanes (Table 2). Although the
numbers are small these values may be of comparative
interest for other trials.
Curcumin has anti-oxidant, anti-inflammatory and anti-
amyloid effects in vitro and prior studies in animal AD
models make it a promising avenue to pursue in human
AD. There are many possible explanations for the results
of our study including differences in the biology of rodent
models of amyloidosis and human AD [26] and differences
in the metabolism of curcumin between humans and
rodents. It is unclear whether lack of a demonstrable bene-
fit is due to problems with bioavailability of this specific
formulation of curcumin or to inefficacy of curcumin as
an intervention for AD. Further studies of other prepara-
tions of curcumin for AD are ongoing.
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